Implication of the endocannabinoid system in the locomotor hyperactivity associated with congenital hypothyroidism

被引:12
作者
Asua, Teresa [1 ]
Bilbao, Ainhoa [4 ]
Angel Gorriti, Miguel [2 ]
Antonio Lopez-Moreno, Jose [2 ]
del Mar Alvarez, Maria [1 ]
Navarro, Miguel [2 ]
Rodriguez de Fonseca, Fernando [2 ,4 ]
Perez-Castillo, Ana [3 ]
Santos, Angel [1 ]
机构
[1] Univ Complutense, Fac Med, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain
[2] Univ Complutense, Fac Psicol, Dept Psicobiol, E-28040 Madrid, Spain
[3] Univ Autonoma Madrid, Consejo Super Invest Cient, Inst Invest Biomed, E-28049 Madrid, Spain
[4] Hosp Carlos Haya, Fdn Inst Mediterraneo Avance Biomed & Invest, Malaga 29010, Spain
关键词
D O I
10.1210/en.2007-1586
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Alterations in motor functions are well-characterized features observed in humans and experimental animals subjected to thyroid hormone dysfunctions during development. Here we show that congenitally hypothyroid rats display hyperactivity in the adult life. This phenotype was associated with a decreased content of cannabinoid receptor type 1 (CB1) mRNA in the striatum and a reduction in the number of binding sites in both striatum and projection areas. These findings suggest that hyperactivity may be the consequence of a thyroid hormone deficiency-induced removal of the endocannabinoid tone, normally acting as a brake for hyperactivity at the basal ganglia. In agreement with the decrease in CB1 receptor gene expression, a lower cannabinoid response, measured by biochemical, genetic and behavioral parameters, was observed in the hypothyroid animals. Finally, both CB1 receptor gene expression and the biochemical and behavioral dysfunctions found in the hypothyroid animals were improved after a thyroid hormone replacement treatment. Thus, the present study suggests that impairment in the endocannabinoid system can underlay the hyperactive phenotype associated with hypothyroidism.
引用
收藏
页码:2657 / 2666
页数:10
相关论文
共 61 条
  • [1] Windows of vulnerability to psychopathology and therapeutic strategy in the adolescent rodent model
    Adriani, W
    Laviola, G
    [J]. BEHAVIOURAL PHARMACOLOGY, 2004, 15 (5-6): : 341 - 352
  • [2] Developmental expression of tenascin-C is altered by hypothyroidism in the rat brain
    Alvarez-Dolado, M
    González-Sancho, JM
    Bernal, J
    Muñoz, A
    [J]. NEUROSCIENCE, 1998, 84 (01) : 309 - 322
  • [3] THE EFFECTS OF CONGENITAL HYPOTHYROIDISM USING THE HYT/HYT MOUSE ON LOCOMOTOR-ACTIVITY AND LEARNED BEHAVIOR
    ANTHONY, A
    ADAMS, PM
    STEIN, SA
    [J]. HORMONES AND BEHAVIOR, 1993, 27 (03) : 418 - 433
  • [4] Prenatal exposure to the CB1 receptor agonist WIN 55,212-2 causes learning disruption associated with impaired cortical NMDA receptor function and emotional reactivity changes in rat offspring
    Antonelli, T
    Tomasini, MC
    Tattoli, M
    Cassano, T
    Tanganelli, S
    Finetti, S
    Mazzoni, E
    Trabace, L
    Steardo, L
    Cuomo, V
    Ferraro, L
    [J]. CEREBRAL CORTEX, 2005, 15 (12) : 2013 - 2020
  • [5] Nuclear hormone receptors and gene expression
    Aranda, A
    Pascual, A
    [J]. PHYSIOLOGICAL REVIEWS, 2001, 81 (03) : 1269 - 1304
  • [6] Reversal of dopamine D2 receptor responses by an anandamide transport inhibitor
    Beltramo, M
    de Fonseca, FR
    Navarro, M
    Calignano, A
    Gorriti, MA
    Grammatikopoulos, G
    Sadile, AG
    Giuffrida, A
    Piomelli, D
    [J]. JOURNAL OF NEUROSCIENCE, 2000, 20 (09) : 3401 - 3407
  • [7] Thyroid hormone receptors in brain development and function
    Bernal, Juan
    [J]. NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM, 2007, 3 (03): : 249 - 259
  • [8] GENETIC AND CLINICAL-FEATURES OF 42 KINDREDS WITH RESISTANCE TO THYROID-HORMONE - THE NATIONAL-INSTITUTES-OF-HEALTH PROSPECTIVE-STUDY
    BRUCKERDAVIS, F
    SKARULIS, MC
    GRACE, MB
    BENICHOU, J
    HAUSER, P
    WIGGS, E
    WEINTRAUB, BD
    [J]. ANNALS OF INTERNAL MEDICINE, 1995, 123 (08) : 572 - 583
  • [9] CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
  • [10] COMER CP, 1985, NEUROTOXICOLOGY, V6, P25